113 filings
Page 3 of 6
8-K
vpn1jcbzi
14 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
m1pt7lrfbm i5yl
28 Mar 23
Virpax Pharmaceuticals Announces Appointment of
4:05pm
8-K
dqog4rb5
22 Mar 23
Virpax Pharmaceuticals Reports 2022 Year-End Results
9:00am
8-K
c6cuocspky
13 Mar 23
Regulation FD Disclosure
9:11am
8-K
sq7lx
17 Feb 23
Other Events
9:02am
8-K
invdmj02cp89sg6153op
29 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
S-8
u52svtv efak
22 Nov 22
Registration of securities for employees
4:06pm
8-K
b0jl a4ktof644t4
9 Nov 22
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
9:05am
EFFECT
83420ajqd9hk7t4
19 Oct 22
Notice of effectiveness
12:15am
CORRESP
erj0hlsv fiu0uli
14 Oct 22
Correspondence with SEC
12:00am
UPLOAD
5wf4ixbrzy4r j70
13 Oct 22
Letter from SEC
12:00am
S-3
3sdws3v 2ptpwyq3tybg
7 Oct 22
Shelf registration
5:01pm
8-K
54xgqw
15 Aug 22
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
9:10am
8-K
x4eiynbt puofu0q
25 Jul 22
Departure of Directors or Certain Officers
5:01pm
8-K
5la ee4rcc
27 Jun 22
Virpax Will Pursue Direct to OTC Pathway for Epoladermâ„¢ for Pain Associated with Osteoarthritis
4:30pm
DEFA14A
tpnc04v 3i
21 Jun 22
Additional proxy soliciting materials
4:30pm
DEFA14A
61oz07 8zhc
15 Jun 22
Additional proxy soliciting materials
5:20pm